Skip to main content
SpringerLink
Log in

The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

This study aimed at analyzing the therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model and preliminarily explore the mechanism of RANTES in malignant ascites to provide an important reference for applying chemokines in anti-tumor therapy. The murine H22 hepatoma ascites model was used. Three treatment groups were analyzed: a RANTES treatment group, an IL-2 control group, and an NS control group. Two regimens of early treatment and late treatment were designed, and the therapeutic effect of RANTES on malignant ascites was studied by measuring changes in mouse body weight and abdominal circumference and observing the survival time. The expression of TNF-α, IFN-γ, TGF-β1, and MCP-1 in mouse ascites was detected by ELISA, and the chemotactic function of RANTES on B lymphocytes and T lymphocytes was analyzed by flow cytometry. In the early and late treatment regimens, RANTES could effectively inhibit the increase in mouse body weight and abdominal circumference in the murine H22 hepatoma ascites model. The secretion of TNF-α and IFN-γ, which had anti-tumor effects, was higher in the RANTES treatment group than in the control groups (P < 0.05), whereas the secretion of TGF-β1 and MCP-1, which promoted tumor growth, invasion, and metastasis, was lower than in the control groups (P < 0.05). RANTES had chemotactic effects on CD4+ and CD8+ T lymphocytes; therefore, the percentage of CD3, CD4, and CD8 in the mouse ascites in the RANTES treatment group was significantly higher than in the NS control and IL-2 treatment groups, and the CD4/CD8 ratio was also significantly higher. RANTES can effectively inhibit the increase in body weight and abdominal circumference and significantly extend survival time in mice in the H22 hepatoma ascites model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15:59–72

    Article  CAS  Google Scholar 

  2. Seike M, Maetani I, Sakai Y (2007) Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol 22:2161–2166

    Article  PubMed  Google Scholar 

  3. Eissa S, Zaki SA, El-Maghraby SM, Kadry DY (2005) Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Cancer Inst 17:51–55

    Google Scholar 

  4. Zhang J, Wang X, Lu H (2008) Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase. Cancer Lett 260:127–136

    Article  PubMed  CAS  Google Scholar 

  5. Murala S, Alli V, Kreisel D, Gelman AE, Krupnick AS (2010) Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2:237–244

    PubMed  CAS  Google Scholar 

  6. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM (2009) A human T cell-specific molecule is a member of a new gene family. 1988. J Immunol 182:3947–3954

    PubMed  CAS  Google Scholar 

  7. Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, Hatz RA, Urba WJ, Jauch KW, Fox BA, Rüttinger D (2011) Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 3:105–114

    PubMed  CAS  Google Scholar 

  8. Levy JA (2009) The unexpected pleiotropic activities of RANTES. J Immunol 182:3945–3946

    Article  PubMed  CAS  Google Scholar 

  9. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ (1996) RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 7:1545–1553

    Article  PubMed  CAS  Google Scholar 

  10. Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, Planelles V, Rosenblatt JD (1999) Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 93:643–654

    PubMed  CAS  Google Scholar 

  11. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL, Murphy WJ, James K, Taub DD (2000) Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 37:515–526

    Article  PubMed  CAS  Google Scholar 

  12. Lavergne E, Combadiere C, Iga M, Boissonnas A, Bonduelle O, Maho M, Debre P, Combadiere B (2004) Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 173:3755–3762

    PubMed  CAS  Google Scholar 

  13. Park SJ, Hughes MA, Burdick M, Strieter RM, Mehrad B (2009) Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. J Immunol 182:4306–4312

    Article  PubMed  CAS  Google Scholar 

  14. Matsumiya T, Ota K, Imaizumi T, Yoshida H, Kimura H, Satoh K (2010) Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1. J Immunol 184:4205–4214

    Article  PubMed  CAS  Google Scholar 

  15. George J, Banik NL, Ray SK (2009) Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin Cancer Res 15:7186–7195

    Article  PubMed  CAS  Google Scholar 

  16. Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer IH (2009) IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 183:51–58

    Article  PubMed  CAS  Google Scholar 

  17. Olson CM Jr, Bates TC, Izadi H, Radolf JD, Huber SA, Boyson JE, Anguita J (2009) Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. J Immunol 182:3728–3734

    Article  PubMed  CAS  Google Scholar 

  18. Dodig S, Zrinski-Topić R (2009) Serial interferon gamma release assay in latent tuberculosis infection. LabMedicine 40:681–682

    Google Scholar 

  19. Fong YC, Hsu SF, Wu CL, Li TM, Kao ST, Tsai FJ, Chen WC, Liu SC, Wu CM, Tang CH (2009) Transforming growth factor-[beta] 1 increases cell migration and [beta] 1 integrin up-regulation in human lung cancer cells. Lung Cancer 64:13–21

    Article  PubMed  Google Scholar 

  20. Huang T, Kar S, Javle M (2010) Personalized therapy for pancreatic cancer: myth or reality in 2010? J Gastrointest Oncol 1:24–33

    Google Scholar 

  21. Prager GW, Poettler M, Unseld M, Zielinski CC (2012) Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res 1:14–25

    Google Scholar 

  22. Yuan Y, Chen H, Ma G, Cao X, Liu Z (2012) Reelin is involved in transforming growth factor-beta1-induced cell migration in esophageal carcinoma cells. PLoS ONE 7:e31802

    Article  PubMed  CAS  Google Scholar 

  23. Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N, Yoshihara M, Chayama K (2005) Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res 11:7629–7636

    Article  PubMed  CAS  Google Scholar 

  24. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315–322

    Article  PubMed  Google Scholar 

  25. Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC (1999) Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86:1537–1543

    Article  PubMed  CAS  Google Scholar 

  26. Saiki M, Saitoh T, Inoue M, Hatta Y, Yamazaki T, Itoh T, Takeuchi J, Sawada U, Horie T (2002) Human herpesvirus-8 negative primary effusion lymphoma with complete clinical remission after removal of ascites. Rinsho Ketsueki 43:548–553

    PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Higher Education of Science and Technology Development Foundation Planning Projects of Tianjin (No. 20100116) and the Health Bureau Foundation of Tianjin (No. 2010KZ76).

Author information

Authors and Affiliations

  1. Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin, 300060, China

    Chunfang Hao, Yehui Shi, Xueqing Wei, Shufen Li & Zhongsheng Tong

  2. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin, 300060, China

    Jinpu Yu

Authors
  1. Chunfang Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yehui Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinpu Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xueqing Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shufen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhongsheng Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhongsheng Tong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hao, C., Shi, Y., Yu, J. et al. The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model. Mol Cell Biochem 367, 93–102 (2012). https://doi.org/10.1007/s11010-012-1323-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-012-1323-x

Keywords

Search

Navigation